...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>The Journal of Urology >Single photon emission computerized tomography with capromab pendetide plus computerized tomography image set co-registration independently predicts biochemical failure.
【24h】

Single photon emission computerized tomography with capromab pendetide plus computerized tomography image set co-registration independently predicts biochemical failure.

机译：Capromab pendetide的单光子发射计算机断层摄影加上计算机断层摄影图像集的共配准可独立预测生化失败。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

PURPOSE: We evaluate the usefulness of pretreatment (111)Indium capromab pendetide (ProstaScint) planar imaging (immunoscintigraphy) plus single photon emission tomography co-registration with computerized tomography scans to detect occult metastatic disease and predict for biochemical failure, in a cohort of patients with a clinical diagnosis of localized adenocarcinoma of the prostate referred for primary radiotherapy. MATERIALS AND METHODS: Patients were followed after radiotherapy for evidence of biochemical failure using 2 criteria of prostate specific antigen clinical nadir +2 ng/ml and American Society for Therapeutic Radiology and Oncology Consensus definitions. Median followup was 58.8 months (mean 64.8). Clinical risk factors defined 3 risk groups of high (51), intermediate (72) and low (116). RESULTS: Overall biochemical failure was 18.3% vs 11.8% by the 2-BFC at 8-year actuarial analysis with 58.8 months median followup. By the CN +2 definition the control date for the cohort is 34.8 months. Pretreatment SPECT/CT suggested prostate cancer metastasis (22), seminal vesicle extension (20) and organ confined disease (197). Biochemical failure in patients having extra-periprostatic metastatic prostate cancer, seminal vesicle extension and organ confined disease uptake on SPECT/CT was 43.2%, 16.0% vs 14.7% (p = 0.0006); and 33.3%, 15.0% vs 8.7% (p = 0.0017) by the 2-BFC, respectively. Cox multiple regression analysis demonstrated that a finding of extra-periprostatic metastatic prostate on SPECT/CT significantly predicted a 4.2-fold greater risk (p = 0.0012) and a 4.5-fold greater risk (p = 0.0011) of failure by the 2-BFC than organ confined disease adjusting for treatment and risk group. CONCLUSIONS: Unconfirmed findings of extra-periprostatic metastatic prostate cancer on SPECT/CT immunoscintigraphy independently and significantly predicted an increased risk of biochemical failure in patients presenting for radiotherapy with a clinical diagnosis of localized prostate cancer.
机译：目的：我们评估一组患者中的预处理（111）己内酰胺溴化丙锭（ProstaScint）平面成像（免疫闪烁成像）加上单光子发射断层扫描与计算机断层扫描的共同配准，以检测隐匿性转移性疾病并预测生化失败。临床诊断为局部放疗的前列腺癌，需进行初次放疗。材料与方法：放疗后随访患者，以2项前列腺特异抗原临床最低点+2 ng / ml和美国放射治疗与肿瘤学共识学会定义对生化衰竭证据进行随访。中位随访时间为58.8个月（平均64.8）。临床风险因素定义了高（51），中（72）和低（116）3个风险组。结果：8年精算分析中，总体生化失败率为18.3％，而2-BFC为11.8％，中位随访时间为58.8个月。根据CN +2的定义，队列的控制日期为34.8个月。 SPECT / CT预处理提示前列腺癌转移（22），精囊扩张（20）和器官受限疾病（197）。在SPECT / CT上，患有围手术前转移性前列腺癌，精囊扩张和器官受限疾病的患者的生化失败率为43.2％，16.0％和14.7％（p = 0.0006）; 2-BFC分别为33.3％，15.0％和8.7％（p = 0.0017）。 Cox多元回归分析表明，在SPECT / CT上发现前列腺增生前转移性前列腺癌，显着预测2-BFC导致失败的风险高4.2倍（p = 0.0012）和4.5倍（p = 0.0011）。而不是针对治疗和危险人群调整器官受限疾病。结论：在SPECT / CT免疫闪烁照相术上，未经证实的前列腺素外转移性前列腺癌的发现，并显着预测了临床诊断为局部前列腺癌的放射治疗患者生化失败的风险增加。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号